IP Library Granted Patent US 11,413,360
Granted Patent B2
US 11,413,360 · App. 16/634,759 · Granted Aug 16, 2022

Dual mode radiotracer and—therapeutics

Inventors: Alexander Josef Wurzer (Munich, DE); Hans-Jürgen Wester (Ilmmünster, DE); Matthias Johannes Eiber (Vaterstetten, DE)
Assignees: Technische Universität München; Technische Universität München—Klinikum Rechts der Isar
A61K51/0497A61K51/0402A61K51/0482
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,413,360
App. No.
16/634,759
Granted
Aug 16, 2022
Kind
B2
Abstract

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

Claims (24)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt and or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18 F.

2. A pharmaceutical or diagnostic composition comprising or consisting of one or more compounds according to claim 1 , or a pharmaceutically acceptable salt or individual isomer thereof.

3. A method of imaging and/or diagnosing cancer comprising administering a compound according to claim 1 , or a pharmaceutically acceptable salt or individual isomer thereof, to a patient in need thereof; and imaging the patient in need thereof.

4. A method of treating cancer in a patient, comprising administering an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt or individual isomer thereof, to a patient.

5. A method of reducing neoangiogenesis or angiogenesis in a patient in need thereof, comprising administering an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt or individual isomer thereof, to a patient in need thereof.

6. The method according to claim 4 , wherein the cancer is prostate, breast, lung, colorectal or renal cell carcinoma.

7. A method of imaging and/or diagnosing neoangiogenesis or angiogenesis in a patient, comprising administering a compound according to claim 1 , or a pharmaceutically acceptable salt or individual isomer thereof, to a patient in need thereof; and imaging the patient in need thereof.

8. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18 F.

9. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18 F.

10. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18 F.

11. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18 F.

12. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18 F.

13. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18 F.

14. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or individual isomer thereof, optionally containing a chelated nonradioactive or radioactive cation and wherein the fluorine atom is optionally 18 F.

15. The compound according to claim 1 , or a pharmaceutically acceptable salt or individual isomer thereof, wherein the chelated cation is selected from the cations of 43 Sc, 44 SC, 47 Sc, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 90 Y, 111 In, 149 Tb, 152 Tb, 155 Tb, 161 Tb, 166 Ho, 177 Lu, 186 Re, 188 Re, 212 Pb, 212 Bi, 213 Bi, 225 Ac, and 227 Th or a cationic molecule comprising 18 F.

16. The compound according to claim 1 , or a pharmaceutically acceptable salt or individual isomer thereof, wherein the fluorine atom is 18 F.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2020
From: EIBER, MATTHIAS JOHANNES
To: TECHNISCHE UNIVERSITÄT MÜNCHEN - KLINIKUM RECHTS DER ISAR
Reel/Frame 052238/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2020
From: WURZER, ALEXANDER JOSEF; WESTER, HANS-JÜRGEN
To: TECHNISCHE UNIVERSITÄT MÜNCHEN
Reel/Frame 052238/0053 →
Priority Claims (1)
EP 17183795 · Jul 28, 2017 · regional
Continuity (1)
Related Publication 20200197545A1 · Jun 25, 2020
Cited By (3)
US 12,447,217 US 12,527,885 US 12,622,984